New data published in Nature Genetics demonstrate that tiny LNA-based compounds developed by Santaris Pharma A/S inhibit entire disease-associated microRNA families
Tiny LNA-based compounds developed by Santaris Pharma A/S successfully inhibit entire microRNA families, targeting cancer, viral infections, and cardiovascular diseases. The high affinity and target specificity of these compounds enable functional inhibition without off-target effects.